| Name | Title | Contact Details |
|---|
Taranis is a leading precision agriculture intelligence platform that uses sophisticated computer vision, data science and deep learning algorithms to effectively monitor fields. Taranis offers a full-stack solution for high precision aerial surveillance imagery to prevent crop yield loss due to insects, crop Farmers lose 30-40% of their yield every season due to crop diseases, insects, and weeds. Our mission: Help growers maximize crop yield, improve productivity, and adopt sustainable practices in order to ensure prosperity, starting in our local communities and for the benefit of the world. Taranis crop intelligence solutions use deep agronomic expertise and the most advanced AI and submillimeter image technologies to do just that. We make an impact for over 100 agribusinesses, thousands of farmers, and in millions of acres around the world, and grow rapidly. Founded in 2015, Taranis raised over $100M from leading VC investors and is being led by a founding team with vast experience in both agriculture and technology.
With a global footprint spanning Europe, North and South America, Asia, and Africa, Sodecia operates business units that partner with the worlds leading automakers to develop innovative products and services. We specialize in stamping and welding, producing high-quality automotive components. Our technology centers in Europe provide comprehensive collaborative engineering services, delivering solutions that add value through advanced technologies, sustainability, agility, simplicity, and customer satisfaction. Sustainability is at the heart of our operations. We are committed to reducing our environmental impact through various initiatives, including the implementation of cutting-edge technologies and sustainable practices. Our dedication to sustainability ensures that we are not only meeting the needs of today but also preserving resources for future generations. At Sodecia, we believe in continuous improvement and innovation. Our global team is dedicated to enhancing the quality of life through the development of solutions for the automotive sector. Together, we are driving forward to create a safer, more efficient, and sustainable future. Explore more about our mission and values on our website.
Superior Industries is a leading global manufacturer of aluminum wheels for light vehicles, founded in 1957 and based in Southfield, Michigan. The company operates nine manufacturing facilities across North America and Europe, employing around 8,000 people. With over six decades of experience, Superior Industries focuses on innovation in lightweighting and advanced finishing technologies to meet the needs of the automotive market. The company specializes in producing light vehicle aluminum wheels, offering custom finishes and designs. It also has expertise in wheel lightweighting, which enhances fuel efficiency and performance. Superior Industries is publicly traded on the New York Stock Exchange under the ticker SUP and positions itself as a supplier to automotive manufacturers that require high-volume, quality wheel solutions.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.